Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 4218-4223

  Boffito, Marta ^a   Jackson, Akil ^a   Amara, Alieu ^b   Back, David ^b   Khoo, Saye ^b   Higgs, Chris ^a   Seymour, Natalia ^a   Gazzard, Brian ^a   Moyle, Graeme ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DARUNAVIR; RITONAVIR;

ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS; HYPERBILIRUBINEMIA; IC 50; LABORATORY TEST; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SIDE EFFECT; VIRUS ISOLATION; VOLUNTEER; WILD TYPE;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; SULFONAMIDES; YOUNG ADULT;

EID: 80051804579     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01747-10     Document Type: Article

References (19)

1. Boffito, M., et al. 2008. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. Antivir. Ther. 13:901-907.
2. Boffito, M, and A. Hill. 2007. Effect of protease inhibitors on ritonavir pharmacokinetics, abstr. 50. 8th Int. Workshop Clin. Pharmacol. HIV Ther., Budapest, Hungary, 16 to 18 April.
3. Boffito, M., et al. 2004. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 18:1291-1297. (Pubitemid 38822707)
4. Boffito, M., D. Miralles, and A. Hill. 2008. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naive and -experienced patients. HIV Clin. Trials 9:418-427.
5. Bristol-Myers Squibb. 2007. Reyataz (R) (atazanavir). Summary of product characteristics. Bristol-Myers Squibb, Uxbridge, United Kingdom.
6. Busti, A J, R G Hall, and D M Margolis. 2004. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 24:1732-1747. (Pubitemid 39578961)
7. Cohen, C., et al. 2004. The FOTO study: a pilot study of short-cycle treatment interruption, taking antiretroviral medications for five days on, two days off (FOTO) for those with viral load suppression, abstr. TUPEB4575. XV Int. AIDS Conf., Bangkok, Thailand, 11 to 16 July 2004.
8. Cohen, C J, A E Colson, A G Sheble-Hall, K A McLaughlin, and G D Morse. 2007. Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. HIV Clin. Trials 8:19-23. (Pubitemid 46542906)
9. Dickinson, L., S. Khoo, and D. Back. 2008. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Curr. Opin. HIV AIDS 3:296-305. (Pubitemid 351521014)
10. Else, L., et al. 2010. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J. Chromatogr B Analyt. Technol. Biomed. Life Sci. 878:1455-1465.
11. Gazzard, B., et al. 2006. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med. 7:487-503. (Pubitemid 44742349)
12. Glass, T R, et al. 2010. Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. J. Acquir. Immune Defic. Syndr. 54:197-203.
13. Hill, A., J. Van der Lugt, W. Sawyer, and M. Boffito. 2009. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials. AIDS 23:2237-2245.
14. la Porte, C., et al. 2006. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev. Antiviral Ther. 3:4-14.
15. McKeage, K., C M Perry, and S J Keam. 2009. Darunavir: A review of its use in the management of HIV infection in adults. Drugs 69:477-503.
16. Moyle, G J, and D. Back. 2001. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med. 2:105-113. (Pubitemid 33114749)
17. Raboud, J., et al. 28 September 2010. Once Daily Dosing Improves Adherence to Antiretroviral Therapy. AIDS Behav. doi: 10.1007/s10461-010-9818-5.
18. Sekar, V., et al. 2008. Pharmacokinetic-pharmacodynamic analyses of once-daily darunavir in the ARTEMIS study, abstr. L-103. Abstr. 15th Conf. Retrovir. Oppor. Infect., Boston, MA, 3 to 6 February 2008.
19. Sekar, V., et al. 2006. Absence of TMC114 exposure-efficacy and exposure-safety relationships in POWER 3, abstr. TUPE0078. XVI Int. AIDS Conf., Toronto, Canada, 13 to 18 August 2006.